Literature DB >> 27886787

Rheumatic Heart Disease: The Unfinished Global Agenda.

Shanti Nulu1, Gene Bukhman2, Gene F Kwan3.   

Abstract

Primarily affecting the young, rheumatic heart disease (RHD) is a neglected chronic disease commonly causing premature morbidity and mortality among the global poor. Standard clinical prevention and treatment is based on studies from the early antimicrobial era, as research investment halted soon after the virtual eradication of the disease from developed countries. The emergence of new global data on disease burden, new technologies, and a global health equity platform have revitalized interest and investment in RHD. This review surveys past and current evidence for standard RHD diagnosis and treatment, highlighting gaps in knowledge. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Global health; Noncommunicable disease; Rheumatic fever; Rheumatic heart disease

Mesh:

Year:  2017        PMID: 27886787     DOI: 10.1016/j.ccl.2016.08.006

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  8 in total

1.  Rheumatic Heart Disease Still Relevant.

Authors:  Carsten Krüger
Journal:  Dtsch Arztebl Int       Date:  2017-08-21       Impact factor: 5.594

2.  Rheumatic Heart Disease Patients' Adherence to Secondary Prophylaxis and Associated Factors at Hospitals in Jimma Zone, Southwest Ethiopia: A Multicenter Study.

Authors:  Alinur Adem; Tadesse Dukessa Gemechu; Habtemu Jarso; Wondu Reta
Journal:  Patient Prefer Adherence       Date:  2020-12-04       Impact factor: 2.711

3.  Global burden of rheumatic heart disease: trends from 1990 to 2019.

Authors:  Zejin Ou; Danfeng Yu; Yuanhao Liang; Jinhua Wu; Huan He; Yongzhi Li; Wenqiao He; Yuhan Gao; Fei Wu; Qing Chen
Journal:  Arthritis Res Ther       Date:  2022-06-11       Impact factor: 5.606

4.  The American Heart Association 2030 Impact Goal: A Presidential Advisory From the American Heart Association.

Authors:  Sonia Y Angell; Michael V McConnell; Cheryl A M Anderson; Kirsten Bibbins-Domingo; Douglas S Boyle; Simon Capewell; Majid Ezzati; Sarah de Ferranti; Darrell J Gaskin; Ron Z Goetzel; Mark D Huffman; Marsha Jones; Yosef M Khan; Sonia Kim; Shiriki K Kumanyika; Alexa T McCray; Robert K Merritt; Bobby Milstein; Dariush Mozaffarian; Tyler Norris; Gregory A Roth; Ralph L Sacco; Jorge F Saucedo; Christina M Shay; David Siedzik; Somava Saha; John J Warner
Journal:  Circulation       Date:  2020-01-29       Impact factor: 29.690

5.  Comparison Between Different Strategies of Rheumatic Heart Disease Echocardiographic Screening in Brazil: Data From the PROVAR (Rheumatic Valve Disease Screening Program) Study.

Authors:  Bruno R Nascimento; Craig Sable; Maria Carmo P Nunes; Adriana C Diamantino; Kaciane K B Oliveira; Cassio M Oliveira; Zilda Maria A Meira; Sandra Regina T Castilho; Júlia P A Santos; Letícia Maria M Rabelo; Karlla C A Lauriano; Gabriel A L Carmo; Allison Tompsett; Antonio Luiz P Ribeiro; Andrea Z Beaton
Journal:  J Am Heart Assoc       Date:  2018-02-14       Impact factor: 5.501

6.  miRNA-1183-targeted regulation of Bcl-2 contributes to the pathogenesis of rheumatic heart disease.

Authors:  Ni Li; Linwen Zhu; Hua Zhou; Dawei Zheng; Guodong Xu; Lebo Sun; Jianqing Gao; Guofeng Shao
Journal:  Biosci Rep       Date:  2020-11-27       Impact factor: 3.840

7.  Valvular Heart Disease in a Young Israeli Ethiopian Immigrant Population From the Gondar Region With Implications for Rheumatic Heart Disease.

Authors:  Daniel Lyon Fink; Yoram Chaiter; Samuel Menahem; Rivka Farkash; Yossy Machluf
Journal:  Front Public Health       Date:  2018-05-14

Review 8.  Generating Global Priority for Addressing Rheumatic Heart Disease: A Qualitative Policy Analysis.

Authors:  Yusra Ribhi Shawar; Jeremy Shiffman
Journal:  J Am Heart Assoc       Date:  2020-04-20       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.